Login to Your Account



Companion Diagnostics in Driver's Seat

FDA's Draft Guidance Changes Game in Early Alzheimer's

By Marie Powers
Staff Writer

Friday, March 15, 2013
Last month, the FDA's Center for Drug Evaluation and Research issued a draft guidance on the development of drugs in early stage Alzheimer's disease (AD). Intended as a conversation starter, the draft lays out a potential approach to select subjects with early AD and those at risk of developing the disease for enrollment into clinical trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription